Phase 2 clinical trial of DS-1211 begins for individuals with Pseudoxanthoma Elasticum

A Phase 2 clinical trial has started of DS-1211 in individuals with Pseudoxanthoma Elasticum (PXE), a rare multisystem genetic disease that causes calcium deposits in soft tissue resulting in considerable morbidity.

Related Keywords

Michael Jackson ,Daiichi Sankyo ,Sanford Burnham Prebys ,Pseudoxanthoma Elasticum ,Emily Henderson ,Chemical Genomics Prebys Center ,Institute Conrad Prebys Center ,Prebys Center ,Sanford Burnham ,Luis Mill ,Discovery Industry Focus ,Conrad Prebys Center ,Chemical Genomics ,Clinical Trial ,Ecalcification ,Calcium ,Dancer ,Drug Discovery ,Enetic ,Olecule ,Mh ,Research ,